Displaying items by tag: department of microbiology

MicroCT of infected human lung tissue, along with histology and immunohistochemistry, was used to construct images of TB granulomas, airways and vasculature.

This novel virulence trait, which increases severity of S. pneumoniae superinfection, involves pneumococcal surface protein A, now identified as an adhesin.

A comprehensive health-screening program in rural northern KwaZulu-Natal has found a high burden of undiagnosed or poorly controlled non-communicable diseases.

A single intranasal dose provided sterilizing immunity — no detectable COVID-19 virus — in the lungs of vaccinated mice, in contrast to dense infection in lungs of unvaccinated mice.
Knowledge of the specific flagellins that drive the pathogenic immune response in Crohn’s disease is a step toward a potential preventive treatment.
A bilingual speaker of Japanese, Leanna Miku Crafford volunteered with a nonprofit health care clinic, did research in microbiology and led the Japanese Culture Club. She will graduate May 1 with honors magna cum laude with a Bachelor of Science degree in biology.
This transport system may be widespread across many Gram-positive bacteria that contain proteins in the WXG100 superfamily. Tuberculosis kills 1 million people each year.

Preclinical tests at UAB last year showed potent systemic and mucosal immune responses in mice after a single intranasal dose. The vaccine candidate was developed by Maryland-based Altimmune Inc.

Streptococcus pneumoniae is an opportunistic pathogen that commonly infects young children and the elderly. This atlas will help researchers better understand how to treat these infections.
Maryland-based Altimmune Inc. has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal candidate.
Layers of tannic acid and another biopolymer delay allograft and autoimmune-mediated rejection in mouse models of Type 1 diabetes.
A monoclonal antibody is being developed by Aridis Pharmaceuticals as an inhaled, self-administered treatment for non-hospitalized patients who are suffering from mild to moderate COVID-19.
Page 3 of 8